Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Articles|January 24, 2022
Daily Medication Pearl: Kovaltry (Antihemophilic Factor)
Author(s)Saro Arakelians, PharmD
Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.
Advertisement
Medication Pearl of the Day: Kovaltry (Antihemophilic Factor)
Indication: Kovaltry Antihemophilic Factor (Recombinant), is a recombinant, human DNA sequence-derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A.
Insight:
- Dosing:
- Required dose (IU) = body weight (kg) x desired Factor VIII rise (% of normal or IU/dL) x reciprocal of expected/observed recovery (e.g., 0.5 for a recovery of 2 IU/dL per IU/kg).
- Estimated Increment of Factor VIII (IU/dL or % of normal) = [Total Dose (IU)/body weight (kg)] x 2 (IU/dL per IU/kg).
- Dosage forms: Kovaltry is available as lyophilized powder in single-dose vials containing nominally 250, 500, 1000, 2000, or 3000 IU. Each vial of Kovaltry contains the labeled amount of recombinant Factor VIII in IU.
- Adverse events: The most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients/minimally treated patients, pyrexia, headache, and rash.
- Mechanism of action: Kovaltry temporarily replaces the missing clotting Factor VIII that is needed for effective hemostasis.
- Manufacturer: Bayer
Sources:
Advertisement
Related to this article
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5